Stryker Corporation
NYSE:SYKMedical - Devices
+$9.29 today
- Market cap
- $121.12B
- Beta
- 0.79
- P/E (TTM)
- 35.6
- EPS (TTM)
- $8.72
- Dividend yield
- 1.11%
Volume 3.25M
Average 2.49M
SYK Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Stryker CorporationNYSE: SYK
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $296M rose 0.0% year over year, behind the +13.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.3% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.
Context
- Depreciation & amortization amounted to 4.7% of revenue in FY2025, up 0.1 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +13.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.19B USD
- Year-over-year change
- +13.6%
- 4-year CAGR
- +4.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.19B | +13.6% |
| FY2024 | 2024-12-31 | 1.05B | +2.1% |
| FY2023 | 2023-12-31 | 1.03B | +3.0% |
| FY2022 | 2022-12-31 | 998M | +0.8% |
| FY2021 | 2021-12-31 | 990M | — |
Depreciation & Amortization vs competitors
How SYK compares with its peers on the latest reported figures
- SYK's LTM Jun 2026 depreciation & amortization of $1.25B is the 2nd largest of the 11 companies compared; the peer median is $216.94M.
- Its year-over-year change of +13.3% is the 2nd highest of 11, against a peer median of +3.5%.
- Depreciation & amortization amounts to 4.8% of revenue for SYK, versus a peer median of 9.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $2.85B | -3.4% | +3.1% | 7.6% | |
| LTM Jun 2026 | $1.25B | +13.3% | +6.1% | 4.8% | |
| LTM Jun 2026 | $1.11B | +6.5% | +5.7% | 13.0% | |
| FY2025 | $573M | +3.2% | +1.5% | 9.3% | |
| LTM Apr 2026 | $297.05M | +3.2% | +10.2% | 13.0% | |
| LTM Jun 2026 | $280.81M | +3.3% | +59.5% | 8.9% | |
| LTM Mar 2026 | $153.07M | +3.8% | +8.7% | 9.3% | |
| LTM Mar 2026 | $136.43M | +43.1% | +37.4% | 16.5% | |
| LTM Mar 2026 | $88.73M | +3.7% | +33.7% | 11.3% | |
| LTM Mar 2026 | $60.2M | -10.3% | +2.2% | 4.4% | |
| LTM Mar 2026 | $4.68M | +9.1% | +59.3% | 3.8% | |
| Peer median (excluding SYK) | $216.94M | +3.5% | +9.5% | 9.3% | |
Competitors are the stored peer set for SYK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
| Depreciation & Amortization | 990M | 998M | 1.03B | 1.05B | 1.19B |
| Deferred Income Tax | (237M) | 58M | (206M) | (370M) | 392M |
| Stock-Based Compensation | 171M | 168M | 205M | 229M | 243M |
| Change in Working Capital | 279M | (732M) | (500M) | (683M) | (373M) |
| Accounts Receivables | (377M) | (579M) | (175M) | (321M) | 127M |
| Inventory | (189M) | (762M) | (797M) | (206M) | (297M) |
| Accounts Payables | 329M | 290M | 77M | 192M | 94M |
| Other Working Capital | 516M | 319M | 395M | (348M) | (297M) |
| Other Non-Cash Items | 66M | (226M) | 19M | 1.02B | 343M |
| Operating Cash Flow | 3.26B | 2.62B | 3.71B | 4.24B | 5.04B |
| Capital Expenditures | (525M) | (588M) | (575M) | (755M) | (761M) |
| Acquisitions (Net) | (339M) | (2.56B) | (390M) | (1.63B) | (4.8B) |
| Purchases of Investments | (49M) | (52M) | (52M) | (808M) | 0 |
| Sales of Investments | 55M | 240M | 54M | 148M | 750M |
| Other Investing Activities | (1M) | 39M | 1M | 43M | (60M) |
| Investing Cash Flow | (859M) | (2.92B) | (962M) | (3B) | (4.87B) |
| Debt Repayment | (1.15B) | 472M | (277M) | 940M | 1.58B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (114M) | (122M) | (155M) | (195M) | (149M) |
| Dividends Paid | (950M) | (1.05B) | (1.14B) | (1.22B) | (1.28B) |
| Other Financing Activities | (148M) | (48M) | (23M) | (51M) | (33M) |
| Financing Cash Flow | (2.37B) | (749M) | (1.59B) | (525M) | 113M |
| Effect of Forex Changes | (38M) | (51M) | (28M) | (36M) | 68M |
| Net Change in Cash | 1M | (1.1B) | 1.13B | 681M | 359M |
| Free Cash Flow | 2.74B | 2.04B | 3.14B | 3.49B | 4.28B |
Stryker Corporation
NYSE:SYK
Intrinsic Alpha fair value
Locked
Current Price
$318.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.